Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Pfizer's Coronavirus Vaccine Is 52.4% Effective After First Dose

By Cory Renauer - Dec 8, 2020 at 10:06AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

That conclusion is based on a new, unfiltered look at clinical trial data from the BNT162b2 program.

On Monday morning, the FDA published briefing documents for an upcoming meeting of a panel of independent medical experts who will weigh in on data from the most closely watched vaccine study in the agency's history. This offered the public its first unfiltered look at the clinical trial results that Pfizer ( PFE 1.77% ) and BioNTech ( BNTX -4.91% ) submitted to support their request for emergency use authorization (EUA) for their coronavirus vaccine candidate, BNT162b2, and the biggest reveal so far is a positive one.

A single-dose of BNT162b2 appears effective

You may remember that BNT162b2 leaped over the  50% efficacy bar set by the FDA. Volunteers were shown to be 94.8% less likely to test positive for COVID-19 seven days or longer after receiving their second dose of the vaccine candidate.

According to the briefing document, a total of 121 volunteers tested positive for COVID-19 during the three-week period between their first and second injections. Since 82 of those cases occurred among volunteers randomized to receive a placebo, we can say BNT162b2 is 52.4% effective at preventing COVID-19 following the first dose, with some caveats.

Child getting a vaccine injection.

Image source: Getty Images.

It's important to remember that there wasn't a separate group of patients given just one dose; the vast majority of volunteers received their second injections as planned. Given that, we can't be confident a single dose of BNT162b2 will remain at least 50% effective for more than a few weeks.

This week's reveal won't change plans to distribute BNT162b2 in a two-dose regimen, but it's still terrific news from a public health perspective. The problem of people missing their booster shots has long been a pain point for public health officials.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$54.68 (1.77%) $0.95
BioNTech SE Stock Quote
BioNTech SE
BNTX
$334.48 (-4.91%) $-17.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/02/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.